scholarly journals Efficacy of Botulinum toxin type A in treatment of different forms of focal dystonias in the Serbian population: Experience of the Botulinum Toxin Outpatients Department

2015 ◽  
Vol 72 (12) ◽  
pp. 1069-1073
Author(s):  
Aleksandra Tomic ◽  
Balsa Vujovic ◽  
Marina Svetel ◽  
Natasa Dragasevic-Miskovic ◽  
Igor Petrovic ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Side Effects ◽  
Rating Scales ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Term Treatment ◽  
Long Term Treatment ◽  
Spastic Torticollis

Background/Aim. Botulinum toxin (BTX) irreversibly inhibits presynaptic acetylcholine release with subsequent relaxation of abnormally contracting muscles. It is an effective and well tolerated treatment with long-term benefit in a variety of movement disorders and other neurological and non-neurological disturbances. The aim of our study was to present our experience with BTX type A in treatment of different forms of focal dystonias. ?ethods. ? hundred of patients with different focal dystonias (spastic torticollis, blepharospasm and graphospasm) from the Botulinum Toxin Outpatients Department, Clinic for Neurology, Clinical Center of Serbia, were included in the study. All the patients were examined and rated at baseline visit prior to BTX application and on the following visit, after 3-4 months, using self-assessment improvement questionnaire and standardized rating scales. Results. The improvement of ? 50% was presented in 68.2% of all (199) the analyzed applications. Independent predictors of good response to the therapy (improvement ? 50%) were male sex (p = 0.011), the presence of sensory trick (p = 0.013) and the total number of BTX applications (p = 0.002). The patients with spastic torticollis and blepharospasm showed a statistically significantly better BTX effect (improvement 57.3 ? 27.5% and 54.1 ? 28.3%), respectively than the graphospasm group (26.7 ? 25.6%). Most of the patients did not have therapy complications (81.4% and 72% in two applications). Side effects in the remaining patients (muscle weakness, dysphagia, ptosis, double vision, neck weakness and lacrimal dysfunction) lasted for 28.3 ? 18.6 days after the first treatment and 32.5 ? 36.2 days after the second one. Conclusion. BTX is safe and highly effective in long-term treatment of patients with different forms of focal dystonia, with only mild and well-tolerated side-effects.

Long-term treatment with botulinum toxin type A in hemifacial spasm

Toxicon ◽  
2008 ◽  
Vol 51 ◽  
pp. 30-31
Author(s):  
Kollewe Katja ◽  
Krampfl Klaus ◽  
Bigalke Hans ◽  
Dengler Reinahrd ◽  
Mohammadi Bahram
Keyword(s):  
Botulinum Toxin ◽  
Hemifacial Spasm ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Term Treatment ◽  
Long Term Treatment

Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay

2008 ◽  
Vol 23 (10) ◽  
pp. 1353-1360 ◽  
Author(s):  
Mitchell F. Brin ◽  
Cynthia L. Comella ◽  
Joseph Jankovic ◽  
Francis Lai ◽  
Markus Naumann ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Cervical Dystonia ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Term Treatment ◽  
Protection Assay ◽  
Long Term Treatment

1.310 Botulinum toxin type A in simple motor tics: Analysis of long-term treatment

2007 ◽  
Vol 13 ◽  
pp. S79
Author(s):  
J. Rath ◽  
D. Tavy ◽  
A. Wertenbroek ◽  
T. van Woerkom ◽  
S. de Bruijn
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Term Treatment ◽  
Simple Motor ◽  
Long Term Treatment ◽  
Motor Tics

Botulinum toxin type A in simple motor tics: Short-term and long-term treatment-effects

2010 ◽  
Vol 16 (7) ◽  
pp. 478-481 ◽  
Author(s):  
Judith J.G. Rath ◽  
Dénes L.J. Tavy ◽  
Agnes A.A.C.M. Wertenbroek ◽  
Theodoor C.A.M. van Woerkom ◽  
Sebastiaan F.T.M. de Bruijn
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Term Treatment ◽  
Short Term ◽  
Simple Motor ◽  
Long Term Treatment ◽  
Motor Tics

Long-term treatment of spasticity with botulinum toxin type A

Toxicon ◽  
2008 ◽  
Vol 51 ◽  
pp. 31-32
Author(s):  
Mohammadi Bahram ◽  
Baloush Shokufeh ◽  
Krampfl Klaus ◽  
Bigalke Hans ◽  
Dengler Reinhard ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Term Treatment ◽  
Long Term Treatment

Experience with long-term treatment with albumin-supplemented botulinum toxin type A

2009 ◽  
Vol 116 (4) ◽  
pp. 437-441 ◽  
Author(s):  
Bahram Mohammadi ◽  
Katja Kollewe ◽  
Maresa Wegener ◽  
Hans Bigalke ◽  
Reinhard Dengler
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Term Treatment ◽  
Long Term Treatment

CONDUCTING COMPARATIVE CLINICAL-PHARMACOLOGICAL EVALUATION PHARMACOTHERAPY PREPARATIONS OF BOTULINUM TOXIN A IN CHILDREN WITH CEREBRAL PALSY SYNDROME WITH MARKED SPASTICITY

2019 ◽  
Vol 25 (5-6) ◽  
pp. 293-302
Author(s):  
Anna Petrovna Solovieva ◽  
Vladimir Vladimirovich Arkhipov ◽  
Dmitry Vladimirovich Goryachev
Keyword(s):  
Cerebral Palsy ◽  
Botulinum Toxin ◽  
Botulinum Toxin A ◽  
Pharmacoeconomic Analysis ◽  
Botulinum Toxin Type A ◽  
Botulinum Toxin Type ◽  
Term Treatment ◽  
Long Term Treatment ◽  
Clinical Pharmacological Evaluation

The original methodology for retrospective clinical studies on the criteria of “efficiency/safety” and pharmacoeconomics on the criteria of “cost/effectiveness”is proposed. The results of a retrospective study of medical records in 169 patients with cerebral palsy, which showed that the use of drugs botulinum toxin type A is an important integral component in the long-term treatment of children with spastic forms of cerebral palsy. Presents the results of pharmacoeconomic analysis of the treatment of the syndrome of spasticity in cerebral palsy when used in the complex treatment of Dysport, Botox and Xeomin.

scholarly journals Treatment of hemifacial spasm with botulinum toxin type a: effective, long lasting and well tolerated

2017 ◽  
Vol 75 (2) ◽  
pp. 87-91 ◽  
Author(s):  
Jean Pierre Mette Batisti ◽  
Alais Daiane Fadini Kleinfelder ◽  
Natália Bassalobre Galli ◽  
Adriana Moro ◽  
Renato Puppi Munhoz ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Side Effects ◽  
Hemifacial Spasm ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Term Effect ◽  
Long Term Effect

ABSTRACT Hemifacial spasm (HFS) is a common movement disorder characterized by involuntary tonic or clonic contractions of the muscles innervated by the facial nerve. Objective To evaluate the long-term effect of botulinum toxin type A (BTX-A) in the treatment of HFS. Methods A retrospective analysis of patients treated at the Movement Disorders Outpatient Clinic in the Neurology Service, Hospital de Clínicas, Federal University of Paraná, Curitiba, from 2009 to 2013 was carried out. A total of 550 BTX-A injections were administered to 100 HFS patients. Results Mean duration of improvement following each injection session was 3.1 months, mean latency to detection of improvement was 7.1 days and mean success rate was 94.7%. Patients were evaluated at an interval of 5.8 months after each application. Adverse effects, which were mostly minor, were observed in 37% of the patients at least once during follow-up. The most frequent was ptosis (35.1%). Conclusion Treatment of HFS with BTX-A was effective, sustainable and safe and had minimal, well-tolerated side effects.

Sign in / Sign up

Export Citation Format

Share Document